Fresenius

$2.58 Billion Apheresis Market - Global Growth, Trends, Covid-19 Impact, and Forecasts 2021-2026: Extensive Application of Plasma Therapy to Treat COVID-19 Patients - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 19, 2021
Medical devices, Health, Infectious diseases, Hospitals, Surgery, Other Health, Medicine, Clinical medicine, Transfusion medicine, Hematology, Branches of biology, Bad Homburg vor der Höhe, Apheresis, Fresenius

b'The "Apheresis Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Apheresis Market is valued at approximately USD 1,639 million in 2020 and is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period.\nThe Apheresis market is expected to be positively impacted during the COVID-19 pandemic owing to the extensive application of plasma therapy in the treatment of COVID-19 infected patients.

Key Points: 
  • b'The "Apheresis Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Apheresis Market is valued at approximately USD 1,639 million in 2020 and is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period.\nThe Apheresis market is expected to be positively impacted during the COVID-19 pandemic owing to the extensive application of plasma therapy in the treatment of COVID-19 infected patients.
  • Apheresis plays a vital role in the purification of blood in patients with kidney disorders and thus drives the studied market.
  • With increasing government initiatives, there is an awareness among people, which is further driving the growth of the market studied.
  • Additional the strategic alliances and new product launches by the major companies is expected to drive market growth.\nFor instance, in Jan 2020, Fresenius Kabi invested EUR 30 million for the expansion of transfusion and apheresis disposables plant in Dominican Republic.\n'

Fresenius Medical Care North America Introduces Kinexus Connected Health Platform for Home Dialysis

Retrieved on: 
Tuesday, May 18, 2021
Medicine, Clinical medicine, Health sciences, Bad Homburg vor der Höhe, Renal dialysis, Private providers of NHS services, Membrane technology, Fresenius, Societates Europaeae, Home hemodialysis, Dialysis, Peritoneal dialysis

b'WALTHAM, Mass., May 18, 2021 /PRNewswire/ -- Fresenius Medical Care North America\'s (FMCNA) Renal Therapies Group introduces the Kinexus Therapy Management Platform , a new connected health platform for home dialysis that supports the management of a patient\'s peritoneal dialysis therapy on the Liberty Select cycler.

Key Points: 
  • b'WALTHAM, Mass., May 18, 2021 /PRNewswire/ -- Fresenius Medical Care North America\'s (FMCNA) Renal Therapies Group introduces the Kinexus Therapy Management Platform , a new connected health platform for home dialysis that supports the management of a patient\'s peritoneal dialysis therapy on the Liberty Select cycler.
  • "Our new connected health system is compatible, agile, and scalable, which will allow for an evolution of new features.
  • Through its industry-leading network of dialysis facilities and outpatient cardiac and vascular labs, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.\n'

PM360 Announces Winners of The Seventh Annual ELITE Awards

Retrieved on: 
Friday, May 14, 2021
Health, OPKO Health, Health promotion, Articles, Fresenius, Health marketing, Galderma, Pharmaceutical marketing

Patient Marketing Team, Kite Pharma, a Gilead Company and Agency Partner: Snow Companies\nPayor Solutions Marketing Team, Boehringer Ingelheim and Agency Partner: Entre Health\nTEPEZZA Marketing Team, Horizon Therapeutics and Agency Partners: A23, Epsilon, WE Communications, Real Chemistry, Lockwood, Mosaic\nThe Fresenius Kabi Parenteral Nutrition Team, Fresenius Kabi and Agency Partner: SFC Group\nXYWAV Launch Team, Jazz Pharmaceuticals and Agency Partners: Scout Marketing, Healix, Hoverstate, and MEI\nAndrew Schorr, Co-Founder, Patient Power and Executive Vice President, Remedy Health Media\nSnehal S. Katare, Head of Innovation and Strategy, MedTrix Healthcare LLC\nRodney Spady, Senior Director, U.S. MCM and Digital Strategies Head, Teva Pharmaceuticals\nAli Castro, Senior Director Reproductive Medicine and Maternal Health Marketing, Ferring Pharmaceuticals, Inc.\nNatalie Cummins, Senior Vice President and Chief Commercial Officer, BioReference Laboratories, Inc., an OPKO Health company\nAlisa Lask, Vice President & General Manager, U.S.

Key Points: 
  • Patient Marketing Team, Kite Pharma, a Gilead Company and Agency Partner: Snow Companies\nPayor Solutions Marketing Team, Boehringer Ingelheim and Agency Partner: Entre Health\nTEPEZZA Marketing Team, Horizon Therapeutics and Agency Partners: A23, Epsilon, WE Communications, Real Chemistry, Lockwood, Mosaic\nThe Fresenius Kabi Parenteral Nutrition Team, Fresenius Kabi and Agency Partner: SFC Group\nXYWAV Launch Team, Jazz Pharmaceuticals and Agency Partners: Scout Marketing, Healix, Hoverstate, and MEI\nAndrew Schorr, Co-Founder, Patient Power and Executive Vice President, Remedy Health Media\nSnehal S. Katare, Head of Innovation and Strategy, MedTrix Healthcare LLC\nRodney Spady, Senior Director, U.S. MCM and Digital Strategies Head, Teva Pharmaceuticals\nAli Castro, Senior Director Reproductive Medicine and Maternal Health Marketing, Ferring Pharmaceuticals, Inc.\nNatalie Cummins, Senior Vice President and Chief Commercial Officer, BioReference Laboratories, Inc., an OPKO Health company\nAlisa Lask, Vice President & General Manager, U.S.
  • Aesthetic Business Unit, Galderma\nMyra Reinhardt, Vice President of Product Innovation & Analytics, Lash Group\nPM360is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries.
  • Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.\nThe journal\'s targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership.
  • Additionally, the "360" in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.\nBy providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/pm360-announces-winners-of-the-s...\n'

Fresenius Medical Care’s International Campaign Recognizes Nurses at the Center of Healthcare

Retrieved on: 
Wednesday, May 12, 2021
Managed care, Health, Practice Management, Bad Homburg vor der Höhe, Private providers of NHS services, Fresenius Medical Care, Fresenius, Germany, Membrane technology, Health care, Dialysis

View the full release here: https://www.businesswire.com/news/home/20210511006311/en/\nOn International Nurses Day 2021, Fresenius Medical Care launches the \xe2\x80\x98Care goes both ways\xe2\x80\x99 campaign, to recognize and support the organization\xe2\x80\x99s nurses and clinical teams throughout Asia Pacific, Europe, Middle East and Africa.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210511006311/en/\nOn International Nurses Day 2021, Fresenius Medical Care launches the \xe2\x80\x98Care goes both ways\xe2\x80\x99 campaign, to recognize and support the organization\xe2\x80\x99s nurses and clinical teams throughout Asia Pacific, Europe, Middle East and Africa.
  • Through its network of 4,110 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 344,476 patients around the globe.
  • These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511006311/en/\n"

DGAP-News: Fresenius Medical Care delivers solid first quarter in light of the COVID-19 pandemic, confirms outlook for 2021

Retrieved on: 
Thursday, May 6, 2021
Bad Homburg vor der Höhe, Private providers of NHS services, Medicine, Fresenius Medical Care, Fresenius, Health care, Germany, Membrane technology, Dialysis

In several countries, Fresenius Medical Care has made its dialysis clinics available for the direct vaccination of patients and, where requested, the general public.

Key Points: 
  • In several countries, Fresenius Medical Care has made its dialysis clinics available for the direct vaccination of patients and, where requested, the general public.
  • On a global basis, about 51 percent of Fresenius Medical Care\'s patients have received at least one vaccination.\nFresenius Medical Care confirms its outlook for FY 2021 as outlined on February 23, 2021.
  • Through its network of 4,110 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 344.476 patients around the globe.
  • These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA\'s reports filed with the U.S. Securities and Exchange Commission.

DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care delivers solid first quarter in light of the COVID-19 pandemic, confirms outlook for 2021

Retrieved on: 
Thursday, May 6, 2021
Bad Homburg vor der Höhe, Private providers of NHS services, Fresenius Medical Care, Fresenius, Germany, Health care, Membrane technology, Vaccination, Dialysis

In several countries, Fresenius Medical Care has made its dialysis clinics available for the direct vaccination of patients and, where requested, the general public.

Key Points: 
  • In several countries, Fresenius Medical Care has made its dialysis clinics available for the direct vaccination of patients and, where requested, the general public.
  • At Fresenius Medical Care\'s U.S. facilities, more than 64% of patients and 47% of dialysis center staff have been at least partially vaccinated.
  • On a global basis, about 51 percent of Fresenius Medical Care\'s patients have received at least one vaccination.\nFresenius Medical Care confirms its outlook for FY 2021 as outlined on February 23, 2021.
  • These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA\'s reports filed with the U.S. Securities and Exchange Commission.

$12.13 Billion Disposable Syringes Market - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021
Pharmaceutical, Other Manufacturing, Medical Supplies, Health, Diabetes, Infectious diseases, Hospitals, Manufacturing, Medical equipment, Life sciences, Medicine, Biotechnology, Drug paraphernalia, BD, Franklin Lakes, New Jersey, Syringe, Fresenius, Injection, Safety syringe, Vaccine

b'The "Disposable Syringes Market Size, Trends & Analysis, By Product Type, By Application, By End Use, And By Region, Global Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global disposable syringes market size is expected to reach USD 12.13 Billion in 2028, and register a CAGR of 5.3% during the forecast period.\nIncreasing prevalence of various chronic diseases, increasing use of botox injections, and high adoption of injectable drugs are key factors driving market revenue growth.\nHigh preference for administering injectable formulations among doctors in case of emergency or for quicker recovery of patients.\nMarket growth can be attributed to major factors such as growing geriatric population, preference for injections over drugs over faster recovery, development of technologically advanced syringes, and need for vaccination and immunization programs globally.\nAccording to estimations by WHO, approximately 16 Billion injections are administered every year globally.

Key Points: 
  • b'The "Disposable Syringes Market Size, Trends & Analysis, By Product Type, By Application, By End Use, And By Region, Global Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global disposable syringes market size is expected to reach USD 12.13 Billion in 2028, and register a CAGR of 5.3% during the forecast period.\nIncreasing prevalence of various chronic diseases, increasing use of botox injections, and high adoption of injectable drugs are key factors driving market revenue growth.\nHigh preference for administering injectable formulations among doctors in case of emergency or for quicker recovery of patients.\nMarket growth can be attributed to major factors such as growing geriatric population, preference for injections over drugs over faster recovery, development of technologically advanced syringes, and need for vaccination and immunization programs globally.\nAccording to estimations by WHO, approximately 16 Billion injections are administered every year globally.
  • This factual information, coupled with need for disposable syringes, that needs to be discarded after one use, to avoid spread of infectious diseases and cross contamination among patients are other major factors driving market growth.\nGrowing number of patient footfall in hospitals, and clinics, coupled with need for collecting blood samples for various tests are key factors expected to drive demand for disposable syringes from hospitals, clinics, and pathological laboratories.\nDisposable syringes are generally made of plastic, if these syringes are not disposed of properly, it can result in severe health issues because of pathogens present in these instruments.
  • These factors could hamper growth of the global disposable syringes market.\nSome Key Findings From the Report:\nAmong the product type segments, the safety syringes segment accounted for the largest revenue share in the global market in 2020, due to its safety features, thus eliminating the risks associated with it.\nAmong the application segments, the therapeutic injections segment accounted for the largest revenue share in the global disposable syringes market in 2020, due to use of disposable syringes for administering insulin to diabetic patients, high prevalence of infectious diseases such as HIV infection, malaria, etc.\nNorth America market accounted for the largest revenue share in the global disposable syringes market in 2020, growing prevalence of diabetes and other chronic diseases in countries in North America.\nThe Asia Pacific market is expected to register the highest revenue growth rate over the forecast period, owing to rapidly developing healthcare sector, increasing prevalence of diabetic population, and growing geriatric population resulting in need for disposable syringes to administer drugs.\nKey players profiled in the report include Braun Medical, Inc., Fresenius Kabi AG, Baxter International, Inc., Flextronics International Vita Needle Company, Terumo Corporation, Novo Nordisk, UltiMed, Inc., Henke-Sass, Wolf, Covidien, Retractable Technologies, Inc., and Becton Dickinson and Company.
  • The market players have adopted various strategies including mergers, acquisitions, partnerships, and new product developments, among other strategies, to stay ahead of the competition and expand market footprint.\nIn July 2020, Becton, Dickinson and Company partnered with the US government for Manufacturing Infrastructure Project for Mass Vaccination Campaigns worth USD 70 Million to support the US vaccination program for controlling spread of COVID-19.\n'

MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs

Retrieved on: 
Wednesday, April 28, 2021
Life sciences, Biotechnology, Articles, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Regulatory affairs, Fresenius, XC2, Amniocentesis

Each employee at MiMedx is laser-focused on ensuring that our products can safely, effectively, and efficiently reach the patients who need them.

Key Points: 
  • Each employee at MiMedx is laser-focused on ensuring that our products can safely, effectively, and efficiently reach the patients who need them.
  • Stevens remarked, \xe2\x80\x9cMiMedx is at the forefront of amniotic tissue biologics at a time when the industry is at an inflection point.
  • Prior to that, Dr. Stevens led Quality Systems and Regulatory Affairs for Fresenius Medical Care, beginning in May 2014.
  • In both roles, he was responsible\xc2\xa0for developing strategic processes for deliverables management and measurement within regulatory affairs systems.

Fresenius Kabi Signs Exclusive U.S. Distribution Agreement with Corvida Medical for the HALO® Closed System Drug-Transfer Device

Retrieved on: 
Thursday, April 1, 2021
Research, Medical devices, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, CSTD, Video games, Halo, Germany, Companies, Closed system drug transfer device, Fresenius Kabi, Corvida Medical

View the full release here: https://www.businesswire.com/news/home/20210401005108/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210401005108/en/
    Fresenius Kabi is now the exclusive U.S. distributor for Corvida Medical's HALO Closed System Drug-Transfer Device.
  • (Photo: Business Wire)
    Under the terms of the agreement, Fresenius Kabi will be the exclusive U.S. distributor for the HALO Closed System Drug-Transfer Device (CSTD).
  • The combination of Fresenius Kabi freeflex/freeflex+ IV solution containers, oncology medicines and Corvida Medicals HALO CSTD allows Fresenius Kabi to provide customers a broad range of products to assist with their oncology needs.
  • Mitch Moeller, CEO of Corvida Medical added, "We believe Fresenius Kabi is a great partner for the HALO Closed System Drug-Transfer Device.

ALSAD Medical is Category Winner in Tech Rocketship Award Europe

Retrieved on: 
Wednesday, March 24, 2021
Health, Health informatics, Articles, Telehealth, Digital health, Health care, Dietitian, Fresenius, Medicine

The application is suitable to be inserted into health and care plans of public or private providers.

Key Points: 
  • The application is suitable to be inserted into health and care plans of public or private providers.
  • ALSAD Medical was established in 2019, as the digital health startup of Netis Informatics, a technology support company focusing on healthcare.
  • The startup collaborated with global medical provider Fresenius Medical Care, Semmelweis Medical University (Budapest) and the Associtation of Hungarian Dietitians to develop its AI-supported digital health application for people living with chronic conditions.
  • ALSAD Medical is now entering the UK and the DACH market seeking local partnerships for regional content and pilots with local health providers.